Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology firm, announced CEO Reenie McCarthy's presentations at three upcoming virtual investor conferences in September 2020. The conferences include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 4:30 pm ET, the Cantor Fitzgerald's Virtual Global Healthcare Conference on September 16 at 8:40 am ET, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23 at 1:40 pm ET. Live webcasts will be available on their website.
- None.
- None.
BOSTON, Sept. 10, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in September:
H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14, 2020
Time: 4:30 pm ET
Cantor Fitzgerald's Virtual Global Healthcare Conference 2020
Date: Wednesday, September 16, 2020
Time: 8:40 am ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 23, 2020
Time: 1:40 pm ET
A live audio webcast of these presentations will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcasts will be archived on Stealth's website for 30 days following the event.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne and Becker muscular dystrophies and Friedreich's ataxia, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical stage candidate, SBT-272, for rare neurodegenerative disease indications following promising preclinical data in amyotrophic lateral sclerosis, or ALS. We have optimized our discovery platform to identify novel mitochondria-targeted compounds, including SBT-259, the SBT-550 series of compounds, and other compounds which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-september-301128017.html
SOURCE Stealth BioTherapeutics Inc.
FAQ
When will Stealth BioTherapeutics present at the H.C. Wainwright Conference?
What is the date and time of the Cantor Fitzgerald Conference presentation by MITO?
What time will MITO present at the Oppenheimer Summit?
Where can I watch the presentations by Stealth BioTherapeutics?
What therapies is Stealth BioTherapeutics focused on?
